Summary
Coronary Artery Bypass (CAB) surgery is performed annually in >700,000 patients to treat coronary artery disease and
prevent myocardial infarction (heart attack). Standard CAB surgery involves a highly invasive open-heart procedure in
arrested/non-beating heart, that is associated with long recovery times and severe complications. The surgeons are seeking
for less invasive, closed chest CAB procedures on beating heart, but current solutions are technically extremely challenging and thereby
only used in €89M and >€192M. Dutch SME AMT Medical has developed the proprietary SAFE-CAB
technology to clinical readiness. To substantially accelerate the market entry of the product, the company partners with a leading European cardiac surgery hospital Deutsches Herzzentrum Berlin and a pan-European clinical/regulatory medical device company HEMEX to
obtain regulatory approval through final clinical validation . To realize European wide-implementation, the consortium is complemented by a surgery training company LifeTec Group and the oldest professional organisation for cardiac surgeons European Society of CardioVascular and Endovascular Surgery.
prevent myocardial infarction (heart attack). Standard CAB surgery involves a highly invasive open-heart procedure in
arrested/non-beating heart, that is associated with long recovery times and severe complications. The surgeons are seeking
for less invasive, closed chest CAB procedures on beating heart, but current solutions are technically extremely challenging and thereby
only used in €89M and >€192M. Dutch SME AMT Medical has developed the proprietary SAFE-CAB
technology to clinical readiness. To substantially accelerate the market entry of the product, the company partners with a leading European cardiac surgery hospital Deutsches Herzzentrum Berlin and a pan-European clinical/regulatory medical device company HEMEX to
obtain regulatory approval through final clinical validation . To realize European wide-implementation, the consortium is complemented by a surgery training company LifeTec Group and the oldest professional organisation for cardiac surgeons European Society of CardioVascular and Endovascular Surgery.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/869922 |
| Start date: | 01-09-2019 |
| End date: | 30-06-2023 |
| Total budget - Public funding: | 2 850 312,00 Euro - 2 182 118,00 Euro |
Cordis data
Original description
Coronary Artery Bypass (CAB) surgery is performed annually in >700,000 patients to treat coronary artery disease andprevent myocardial infarction (heart attack). Standard CAB surgery involves a highly invasive open-heart procedure in
arrested/non-beating heart, that is associated with long recovery times and severe complications. The surgeons are seeking
for less invasive, closed chest CAB procedures on beating heart, but current solutions are technically extremely challenging and thereby
only used in €89M and >€192M. Dutch SME AMT Medical has developed the proprietary SAFE-CAB
technology to clinical readiness. To substantially accelerate the market entry of the product, the company partners with a leading European cardiac surgery hospital Deutsches Herzzentrum Berlin and a pan-European clinical/regulatory medical device company HEMEX to
obtain regulatory approval through final clinical validation . To realize European wide-implementation, the consortium is complemented by a surgery training company LifeTec Group and the oldest professional organisation for cardiac surgeons European Society of CardioVascular and Endovascular Surgery.
Status
CLOSEDCall topic
EIC-FTI-2018-2020Update Date
26-10-2022
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
